HkeyBio Expands Wet Lab Validation Capabilities for AI Drug Discovery

HkeyBio announced in a press release that it is expanding its wet lab validation capabilities and upgrading its contract research organization services to address the increasing demand from AI driven drug discovery platforms focused on autoimmune diseases.

The company has established rapid screening and validation platforms that connect computational drug discovery with in vitro and in vivo testing. These include in vitro functional assays, cytokine profiling, immune cell activation studies, and progressive validation in rodent, humanized mouse, and non human primate models. The goal is to help clients move AI generated drug candidates from computational hits to efficacy data more efficiently.

HkeyBio operates research facilities in Suzhou and Guangxi and maintains support nodes in the United States, Europe, and Australia. Its service network covers major pharmaceutical hubs, providing standardized autoimmune disease models and evaluation systems that integrate single cell sequencing, spatial transcriptomics, and multi omics analysis.

The company’s proprietary platforms, including HKEY NHP MATRIX 3.0 and HKEY NHP onChip 1.1, combine multi omics datasets with cost efficient experimental systems. HkeyBio reports over 1,000 completed autoimmune preclinical projects and support for more than 500 IND submissions. The company plans to continue expanding its model libraries and global service network while strengthening collaboration with AI pharmaceutical partners.